NEW YORK — Jason J. Luke, MD, FACP, assistant professor of Medicine at The University of Chicago Medicine, discussed the current status of the use of combination BRAF/MEK therapy in patients with BRAF-mutated melanoma at HemOnc Today Melanoma and Cutaneous Malignancies.
Publications
Brain may become ‘just another organ’ in treatment of metastatic melanoma
NEW YORK — A new paradigm is evolving for the treatment of brain metastases from melanoma that involves a greater role of systemic therapy, according to a speaker at HemOnc Today Melanoma and Cutaneous Malignancies.
Intralesional therapy ‘here to stay’ for melanoma
NEW YORK — There are many ongoing monotherapy and combination trials of oncolytic agents, according to a speaker at HemOnc Today Melanoma and Cutaneous Malignancies.
Multiple gene mutations may predict recurrence in malignant melanoma
NEW YORK — Patients with primary malignant melanoma are at a higher risk for tumor recurrence if they have mutations in two or more cancer-related genes, according to study results presented at HemOnc Today Melanoma and Cutaneous Malignancies